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Prediction of Response to Temozolomide in Low-Grade
Glioma Patients Based on Tumor Size Dynamics and
Genetic Characteristics
P Mazzocco1, C Barthelemy2, G Kaloshi3, M Lavielle2, D Ricard4, A Idbaih3, D Psimaras3, M-A Renard3, A Alentorn3,
J Honnorat5, J-Y Delattre3, F Ducray5 and B Ribba1*
Both molecular profiling of tumors and longitudinal tumor size data modeling are relevant strategies to predict cancer
patients’ response to treatment. Herein we propose a model of tumor growth inhibition integrating a tumor’s genetic
characteristics (p53 mutation and 1p/19q codeletion) that successfully describes the time course of tumor size in patients with
low-grade gliomas treated with first-line temozolomide chemotherapy. The model captures potential tumor progression under
chemotherapy by accounting for the emergence of tissue resistance to treatment following prolonged exposure to
temozolomide. Using information on individual tumors’ genetic characteristics, in addition to early tumor size measurements,
the model was able to predict the duration and magnitude of response, especially in those patients in whom repeated
assessment of tumor response was obtained during the first 3 months of treatment. Combining longitudinal tumor size
quantitative modeling with a tumor’’s genetic characterization appears as a promising strategy to personalize treatments in
patients with low-grade gliomas.
CPT Pharmacometrics Syst. Pharmacol. (2015) 4, 728–737; doi:10.1002/psp4.54; published online 10 October 2015.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?  First-line temozolomide is frequently used to treat low-
grade gliomas (LGG), which are slow-growing brain tumors. The duration of response depends on genetic characteristics
such as 1p/19q chromosomal codeletion, p53 mutation, and IDH mutations. However, up to now there are no means of
predicting, at the individual level, the duration of the response to TMZ and its potential benefit for a given patient. •
WHAT QUESTION DID THIS STUDY ADDRESS?  The present study assessed whether combining longitudinal tumor
size quantitative modeling with a tumor’s genetic characterization could be an effective means of predicting the response
to temozolomide at the individual level in LGG patients. • WHAT THIS STUDY ADDS TO OUR KNOWLEDGE  For the
first time, we developed a model of tumor growth inhibition integrating a tumor’s genetic characteristics which success-
fully describes the time course of tumor size and captures potential tumor progression under chemotherapy in LGG
patients treated with first-line temozolomide. The present study shows that using information on individual tumors’ genetic
characteristics, in addition to early tumor size measurements, it is possible to predict the duration and magnitude of
response to temozolomide. • HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY AND THERAPEUTICS  Our
model constitutes a rational tool to identify patients most likely to benefit from temozolomide and to optimize in these
patients the duration of temozolomide therapy in order to ensure the longest duration of response to treatment.
Response evaluation criteria such as RECIST—or RANO
for brain tumors—are commonly used to assess response
to anticancer treatments in clinical trials.1,2 They assign a
patient’s response to one of four categories, ranging from
“complete response” to “disease progression.” Yet,
criticisms have been raised regarding the use of such cate-
gorical criteria in the drug development process,3,4 and reg-
ulatory agencies have promoted the additional analysis of
longitudinal tumor size measurements through the use of
quantitative modeling.5 Several mathematical models of
tumor growth and response to treatment have been devel-
oped for this purpose.6,7 These analyses have led to the
identification of a variety of tumor size metrics that can be
used to predict long-term clinical outcomes such as overall
survival.8 For instance, tumor size change 2 months after
the beginning of treatment has been identified as a predic-
tor of overall survival in non-small cell lung cancer5 and in
colorectal cancer.9 This suggests that long-term clinical out-
comes can be predicted on the basis of early tumor size
dynamics.
Low-grade glioma (LGG) is a slow-growing brain tumor
whose management involves the use of repeated magnetic
resonance imaging (MRI) scans to monitor the size of
tumor lesions. Surgery, radiotherapy, and two chemotherapy
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regimens, PCV (procarbazine, CCNU, and vincristine)
and temozolomide (TMZ), constitute the standard of
care.10 Both prognosis and response to treatment—in
particular to TMZ therapy—have been shown to depend
on genetic or molecular characteristics such as 1p/19q
chromosomal codeletion,11,12 p53 mutation,12 and IDH
mutations.13 TMZ is an orally administered molecule
with proven efficacy in the first-line treatment of LGG.14
It is generally given for 1 to 2 years, one cycle per
month. The duration of the treatment is frequently pro-
longed beyond 12 cycles if an ongoing decrease in
tumor size is observed at this time.15 However, until now
there is no way of predicting, at the individual level, the
duration of the response to TMZ and its potential benefit
for a given patient.
We previously proposed a tumor growth inhibition model
to analyze the time-course of mean tumor diameter in LGG
patients receiving chemotherapy or radiotherapy.16 Herein,
we further develop this model to analyze the time-course of
tumor size in patients treated with TMZ, to characterize
potential emergence of resistance to TMZ, and to identify
the impact of a patient’s molecular characteristics on tumor
size kinetic parameters. Finally, we show that the modeling
framework can leverage tumor size data obtained during
the early stages of treatment, i.e., during the first few
months, to forecast tumor response.
METHODS
Patients and observations
We analyzed data from 120 LGG patients treated between
1999 and 2007.12 Data included information on tumor size
in all patients and on up to three molecular (genetic) char-
acteristics in 77 patients: 1p/19q chromosomal codeletion,
p53 overexpression (a surrogate marker for TP53 missense
mutations17), and IDH mutation status. The model was built
using the data from these 77 patients. Among these
patients, information on all molecular characteristics was
available for 42 patients (54.5%), and information on at
least one item of molecular characteristic in 35 patients
(45.5%). The data from the 43 patients without molecular
information were used as an external dataset to evaluate
model quality.
Tumor sizes were measured manually from printed MRI
images and expressed as mean tumor diameter (MTD) in
millimeters, according to the formula MTD5 (2V)1/3, where
V ¼ D13D23D32 is the approximated tumor volume with D1,
D2, and D3 referring to the three largest perpendicular
diameters. The total median duration of the posttreatment
follow-up period for a single patient, which included several
follow-up observations, was 21 months (5 months at mini-
mum and 9.5 years at maximum). We analyzed a total of
952 MTD observations with, on average, 12 observations
per patient (minimum 4 observations and maximum 28).
Histology consisted of grade II oligodendrogliomas (56
patients, 73%), oligoastrocytomas (16 patients, 21%), and
astrocytomas (5 patients, 6%). All patients received TMZ
as first-line treatment. The drug was administered for 5
consecutive days (day 1 to day 5) every 28 days at a daily
dose of 200 mg/m2.
Mathematical model of LGG response to chemotherapy
We recently proposed a mathematical model to describe
MTD dynamics in LGG patients before, during, and after
chemotherapy.16 The model, which distinguishes between
disease-specific and treatment-specific parameters, relies
on the hypothesis that LGG tumors are made up of both
quiescent and proliferative cells, and that both cell types
are sensitive to treatment.18,19 Chemotherapy is assumed
to act by damaging cells’ DNA. The DNA damage leads
proliferative cells to die, whereas quiescent cells with DNA
damage can either repair their lesions and return to a prolif-
erative state or die. Thus, we consider three compartments:
proliferative tissue, denoted P; nondamaged quiescent tis-
sue, denoted Q; and damaged quiescent tissue, denoted
Qp. The sum of the values attributed to the three compart-
ments (PÞ represents the size of the lesion and is com-
pared to the MTD observations.
To allow for MTD increase during TMZ treatment, we
extended the previously proposed model16 by taking into
account the possibility that proliferative cells can repair their
DNA lesions during the division process, instead of immedi-
ately dying, and thus acquire resistance to TMZ. In line
with previous works,9 we implemented acquisition of resist-
ance by assuming that the effect of TMZ concentration on
tumor tissues decreases exponentially with the amount of
time since the beginning of treatment. Both proliferative and
quiescent tissues were considered as having the potential
to acquire resistance to TMZ.
Estimation of population parameters
The model was developed in a population context,20 and
the values of individual-level parameters were assumed to
be log-normally distributed; i.e., for a parameter wi corre-
sponding to an individual patient i, wi=w.expgi where w is
the "typical" (population) value of the parameter, and gi rep-
resents the contribution of the individual i. The values of g
are normally distributed with mean 0. Population and indi-
vidual parameter values were estimated with the SAEM
(Stochastic Approximation of the Expectation Maximization)
algorithm implemented in Monolix 4.2 (Lixoft) using the full
MTD time-course in the 77 patients. We assumed a con-
stant error model, with parameter value a. Model selection
was carried out according to the usual criteria; in particular,
models that achieved lower values of the objective function
(22 3 log likelihood) were considered to provide a better fit
to the data.
Integration of genetic information
The data from the 42 patients with complete molecular sta-
tus (codeletion 1p/19q, p53, and IDH mutations) was used
as a training dataset to obtain statistics on this genetic infor-
mation. We computed the percentage of patients with a
given genetic profile and derived the probability to exhibit it.
So for patients with one or two missing covariates, we could
compute the probability to exhibit the lacking mutation sta-
tus(es), knowing the other(s) one(s). We therefore attributed
genetic characteristics for patients with missing covariates.
In our training dataset, in line with previous literature,12 1p/
19q codeletion and the p53 mutation were mutually exclu-
sive. We incorporated the molecular information into the




model and identified the effect of each status on the tumor
size kinetic parameters. For a given fixed-effect parameter f,
the model used for covariate analysis was of the following
form:
n1 ¼ n03 exp b:statusj
 
(1)
where statusj corresponds to the value of the characteristic
j. As we considered binary variables only, Eq. 1 could be
simplified:
n1 ¼ n03 exp bð Þ
where n0 denotes the population value of the parameter for
the reference group of patients (with non-codeleted 1p/19q
or wild p53), and n1 is the population value for the group of
patients with mutated covariate.
Using this framework, only fixed-effect parameters can
depend on the covariate status while (interindividual) vari-
ability is not concerned, i.e., parameters n0 and n1 will have
the same variability.
We used a stepwise forward/backward modeling strategy
based on progressive inclusion and then exclusion of cova-
riates, where the decision to include or exclude a covariate
was dependent on the covariate’s effect on the objective
function through a log-likelihood ratio test.21
Empirical Bayes estimates to predict LGG response
to temozolomide
Following a Bayesian approach in which population parame-
ter estimates constituted prior information, we analyzed each
patient’s data individually, considering only the MTD observa-
tions prior to treatment and the first MTD observations
obtained after treatment onset, i.e., the observations
obtained in the first 3 months of treatment. If, for a given
patient, no observations were available prior to treatment, we
used only the MTD observations obtained within the first 3
months after treatment onset. Patients for whom no informa-
tion was available for the first 3 months of treatment were
excluded from the analysis. Overall, data from 45 patients
were analyzed. Among these, 31 patients had a single MTD
observation during the first 3 months of treatment, and 14
patients had two MTD observations. When possible, MTD
observations before treatment onset were used to estimate
empirical Bayes estimates (EBEs) of the disease-specific
parameters of the model. The MTD observations after treat-
ment start were then used to estimate the treatment-specific
parameters of the model. EBEs were calculated using Mat-
Lab (MathWorks, Natick, MA) after the population parame-
ters were estimated with Monolix.
To evaluate the capacity of the model to predict individual
tumor response to TMZ treatment, two clinically relevant
metrics were calculated: the duration of response, i.e., the
length of time during which MTD decreases, and the mini-
mal tumor size reached as a result of TMZ effect.
External analysis
In the analysis described above, the model’s predictive
capacity was assessed on patients whose full time-course
data were used to estimate the population parameters;
these population parameters constituted prior information
for the calculation of EBEs. To explore whether this caused
a bias, we subsequently performed predictive analysis on
the 43 "external" patients whose data had been excluded
from the initial model-building process, owing to a lack of
genetic information. In this case, we used early MTD obser-
vations as in the original predictive analysis, but without
covariates.
We then used population parameters to simulate 200
new virtual patients, and we made predictions for these
patients using the model without covariates in a first step,
and we incorporated genetic statuses into the predictions in
a second step.
RESULTS
Tumor size time-course in patients treated with
temozolomide
Figure 1 depicts the time-course of tumor size (mean
tumor diameter) in the 77 LGG patients included in the
analysis. Patients received a median of 18 TMZ cycles
(minimum 2 cycles, maximum 24). Table 1 shows a sum-
mary of the characteristics of the 77 patients. Tumor size
increased linearly before treatment.22 After TMZ onset, an
initial MTD decrease followed by a MTD reincrease was
observed (n5 58, 75%). Median time to tumor progression
was 18 months. In 34 patients MTD a reincrease occurred
during TMZ treatment while in 24 patients it occurred after
TMZ discontinuation. We separated the patients to present
tumor profiles in a clear manner, but it did not impact data
analysis.
Mathematical model of LGG response to temozolomide
Inclusion of a resistance term for the proliferative tissue
resulted in a significantly better model fit (drop of 200
points in the objective function) compared with exclusion of
the resistance term. The model with the inclusion of a
resistance term for the quiescent tissue performed worse.
However, because quiescent cells have the capacity to
repair their DNA lesions, they also contribute to the emer-
gence of resistance by repopulating the proliferative com-
partment. Thus, the final selected model incorporated a
resistance term for the proliferative tissue only:
druginduceddecay ¼ c3KDE3P3C3e2res:t (2)
The term res denotes the resistance parameter. Given the
time scale of data collection compared to the time scale of
TMZ delivery scheduling, we represented a single TMZ cycle
(actually composed of five daily administrations) as a single
bolus administration with corresponding concentration, C,
assumed to undergo exponential decay at a constant rate
KDE (a so-called K-PD approach23). The population value of
KDE parameter was fixed to 8.3 month21 corresponding to a
half-life of 2.5 days, allowing for a residual active concentration
of TMZ after 5 days of treatment. The parameter c is the con-
stant rate for proliferative tissue death (also referred to as the
TMZ efficacy parameter). A schematic view of the model is
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3P2ce2res:t3C3KDE3P; P 0ð Þ ¼ P0
dQ
dt
¼ kPQ3P2 c3C3KDE3Q; Q 0ð Þ ¼ Q0
dQp
dt
¼ c3C3KDE3Q2kQpPQp2dQpQp ; Qp 0ð Þ ¼ 0
P ¼ P1Q1Qp
Overall, the model includes seven parameters and two
initial conditions. Two parameters are disease-specific and
related to tumor growth: the proliferation rate (kP) and the
transfer constant rate (kPQ) from proliferation to quiescence.
The five remaining parameters are related to TMZ action
and effect and are called treatment-specific parameters. In
particular, the constant rate of death of quiescent cells is
denoted dQp and kQpP is the constant rate of transition from
quiescence to proliferation following repair of TMZ-induced
DNA damage. For identifiability reasons, we assumed that
the initial drug effect is the same on P and Q. This is con-
sistent with the biology, as TMZ acts on cells regardless of
their stage in the division process.
Impact of molecular status on tumor size dynamics
The covariate analysis performed with the three molecular
status characteristics showed that p53 mutation could be
included as a covariate of the TMZ efficacy parameter (c).
On the basis of the stepwise forward/backward analysis,
we further determined that chromosomal 1p/19q codeletion
could be included as a covariate on the constant rate kQpP
(transition from quiescence to proliferation following repair
of TMZ-induced DNA damage. The inclusion of these two
model covariates led to a significant drop in the objective
function (126 points; P < 0.01, likelihood-ratio test). In the
Figure 1 Typical tumor size dynamics for the 77 patients included in the analysis. Top, left: MTD time-course before treatment onset
(n577). Top, right: In 21 patients, an ongoing MTD decrease after treatment discontinuation was observed. Bottom, left: Acquired
resistance occurs in 34 patients. MTD time-course shows initial decrease followed by progression during TMZ treatment. Bottom, right:
MTD time-course exhibits initial decrease followed by progression before or after treatment cessation (n5 58).




stepwise analysis procedure, IDH mutation status identified
as having an effect on model parameters when tested inde-
pendently from the two other covariates was not identified
as a significant covariate in the presence of p53 and 1p/
19q information. This is in agreement with the known
redundancy of the genetic information24 and indicates that,
in our model, p53 and 1p/19q information intrinsically inte-
grate IDH information. The parameter estimates of the final
model (including covariates) are presented in Table 2.
Among p53-mutated patients, the value of the TMZ effi-
cacy parameter is 45% lower than among p53-nonmutated
patients, suggesting that TMZ therapy is almost two times
less effective in the former population. This is consistent
with preclinical evidence that p53 mutations decrease sen-
sitivity to TMZ in gliomas.25,26 Likewise, among patients
with the 1p/19q codeletion, the value of kQpP is 15% lower
than among non-codeleted patients, suggesting that among
patients in the former group, DNA-damaged quiescent cells
have less capacity to repair themselves. This finding is con-
sistent with the longer duration of response reported in
codeleted patients.12
Figure 3 shows goodness-of-fit (visual predictive check)
plots for the 77 patients included in the model-building
Table 1 Main characteristics of the 77 low-grade glioma patients included in








Sex, M/F 42/35 25/18
Median age at treatment onset 40 (25–71) 48 (24–72)
Molecular status
1p-19q co-deleted/1p-19q non-co-deleted 23/47 –
p53 mutated/p53 nonmutated 24/35 –






Median number of TMZ cycles 18 (2–24) 18 (4–30)
Median interval between TMZ cycles 31 (21–45) 31 (24–50)
Tumor response
Median time to progression (months) 14.5 (4–90) 12.8 (5–93)
Median duration of treatment (months) 18 (2–24) 18 (3–28)
Figure 2 Schematic view of the model with model’s parameters. P is the proliferative tissue, Q is the nondamaged quiescent tissue,
and Qp is the damaged quiescent tissue. The sum of the values corresponding to the three compartments, P
, is compared to the
MTD observations. Proliferative tissue (P) can become quiescent (Q). TMZ treatment affects both proliferative and quiescent tissues.
Damaged quiescent tissue can either repair its DNA lesions and return to a proliferative state or die due to treatment-induced lesions.
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Table 2 Model parameter estimates with their standard deviations as well as covariate effects of 1p/19q codeletion and p53 mutations
Model parameters Units Estimates CV (%) g-shrinkage (%)
P0 mm 1.72 (21) 143 (11) 18
Q0 mm 32.1 (7) 55.8 (8) 2
kP month
21 0.143 (12) 63.1 (13) 23
kPQ month
21 0.0429 (21) 81 (22) 47
kQpP 1p19q non-codeleted month
21 0.00947 (42) 162 (16) 35
kQpP 1p19q codeleted month
21 0.00807 (49) – –
dQp month
21 0.0188 (19) 86.2 (17) 32
c p53 wild – 0.254 (18) 68.6 (16) 34
cp53 mutated – 0.143 (19) – –
res month21 0.1 (22) 80.5 (26) 57
KDE month21 8.3 (FIXED) 50 (FIXED) 84
a mm 1.73 (3) – –
Parameters are defined in the text. a is the parameter for the constant error model. The residual standard errors are shown in parentheses and are given as
percentages of the estimate values. Interindividual variability (CV) is expressed as percentages. g-shrinkage,37 indicating the tendency of individual parameters
shrinkage towards population value is presented in the last column, and g-shrinkage37 was evaluated at 19%. All parameters were estimated with relative
standard errors less than 50%.
Figure 3 Top, Left: Visual Predictive Check (VPC) diagnostics on the 77 patients included in the (internal) analysis. Dashed lines repre-
sent the 5th, 50th, and 95th percentiles from observed data. The areas represent the 90% confidence interval of the 5th, 50th, and 95th
simulated percentiles. Top, Right: VPC on 43 external patients. Middle, Left: VPC for the internal patients with p53 mutation (n5 24).
Middle, Right: p53 nonmutated patients (n535). Bottom, Left: VPC for 1p/19q codeleted patients (n5 23). Bottom, Right: VPC for 1p/
19q non-codeleted patient (n5 47).




dataset and for the 43 patients included in an external data-
set. These diagnostics indicate good quality of the model,
with and without covariates. The proposed model is able to
capture the variability in patients’ response to TMZ, includ-
ing prolonged response after therapy discontinuation or
emergence of acquired resistance to TMZ during treatment.
Prediction of response to TMZ chemotherapy
Figure 4 shows predictions regarding individual patients’
response durations (left-hand side), represented by Kaplan-
Meier curves, together with observed response durations
that fall in the 95% confidence interval (CI) for almost 2
years after treatment onset. Beyond 2 years, the model
predictions are incorrect, which is not surprising given that
only information until month 3 is taken into account. Nota-
bly, beyond 2 years predicted times to progression are ear-
lier than the actual times to progression. In this respect, the
modeling framework shows a tendency for underestimating
the effect of the treatment. The early part of the Kaplan-
Meier curve also indicates a tendency to predict progres-
sion at a very early time. For a small subset of patients
(n54), the unique MTD point during the first 3 months of
treatment was greater than the MTD at treatment onset,
while successive MTD points showed a significant
response. Integrating this point in our modeling framework
resulted in predicting very early progression. However,
removing these four patients resulted in correcting the early
part of the Kaplan-Meier curve.
Figure 4 also shows predicted vs. observed minimal
tumor size (right-hand side). We evaluated prediction bias
(mean prediction error) and precision (root mean squared
prediction error).27 Prediction bias was 1.89 mm (95% CI
(–0.22, 3.99)) and precision was 7.18 mm (95% CI (4.52,
9.10)). For 90% of the patients (n5 40), the observed mini-
mal tumor size was predicted correctly, with less than 25%
relative error (relative to tumor size at treatment onset); this
corresponds, approximately, to an error of about 1 cm in
MTD. Notably, for each of the 14 patients with two MTD
observations within the 3 first months of treatment, the min-
imal tumor size was predicted with an error of less than
15% (about 6 mm).
Individual predictions for six patients with repeated meas-
urements during the first 3 months of treatment are dis-
played in Figure 5 as an illustration of the method
proposed herein. It shows that the model is also able to
predict tumor time-course, especially for these patients. For
the 10% of patients (n5 5) for whom predictions of minimal
tumor size were incorrect, we observed that, for four of
them, tumor size reduction was unexpectedly characterized
by two phases: an initial moderate decrease in tumor size
within the first 5 months of treatment, followed by a more
pronounced decrease after 5 months. For these four
patients, the model underevaluated the response. Inclusion
of a second MTD observation (obtained after 5 months of
treatment) yielded correct minimal tumor size predictions
for these patients. Tumor response for one additional
patient could not be predicted owing to his/her prolonged
response to treatment (more than 40 months). The model
may not be able to capture such extreme behavior.
Figure 4 Left: Kaplan-Meier curve for observed times to tumor growth together with a model-based confidence interval. Right: Pre-
dicted minimal tumor sizes vs. observed minimal tumor sizes. The vertical lines represent a tolerance of 25% relative to tumor size at
treatment onset. Both times to tumor growth and minimal tumor size were predicted using the observations up to the end of the 3rd
month of treatment.
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We then performed predictive analysis on the 43 "external"
patients. The model successfully predicted the minimal
tumor size for 75% of these patients (bias 24.41 mm
(–7.14, 21.67)). To evaluate whether the reduction in predic-
tive capability was due to the lack of genetic information or
to the fact that these patients’ data were not incorporated as
prior information in model-building, we made predictions for
200 virtual patients. Without covariates, the minimal tumor
size was successfully predicted for 76% of the virtual
patients. When we incorporated genetic statuses, predictive
capacity rose to 87% (bias 0.31 mm (–0.86, 1.49)). These
observations lead us to believe that the reduction in the
model’s predictive capacity for the 43 external patients was
mainly due to the absence of genetic information.
DISCUSSION
Molecular profiling of tumors is a well-known strategy to
personalize anticancer treatments. Another approach is
mathematical modeling.28,29 Mathematical models of tumor
growth and response to treatment allow characterizing
quantitatively the efficacy and toxicity of anticancer agents
and can be used to predict clinical response.7,30 In the
present study, we show that combining longitudinal tumor
size measurements through the use of quantitative model-
ing with a tumor’s genetic characterization is a promising
strategy to personalize treatments in patients with low-
grade gliomas.
Using p53 mutation and 1p/19q codeletion as covariates
significantly improved the model accuracy. In agreement
with the literature, p53 and 1p/19q molecular statuses sig-
nificantly impacted the dynamics of LGG response to treat-
ment: p53 mutation impaired TMZ efficacy and 1p/19q
codeleted tumors had less ability to repair TMZ-induced
DNA lesions in quiescent tissue, thus increasing the overall
efficacy of treatment. IDH mutation status did not provide
useful information on tumor size dynamics beyond the com-
bined information provided by p53 and 1p/19q status. How-
ever, it would be relevant to introduce IDH status as a
Figure 5 Individual tumor size predictions for six patients with repeated assessment of tumor response during the first 3 months of
treatment. Filled circles represent tumor sizes that are used to estimate individual parameters, and empty circles are observations to
be predicted. The dashed lines represent tumor dynamics simulated until the 3rd month of treatment, and the solid line represents the
actual prediction.




model covariate in cases in which p53 and 1p/19q informa-
tion is not available for a given patient.
Molecular information (p53 and 1p/19q status) and tumor
observations obtained during the first 3 months after TMZ
treatment onset were sufficient to correctly predict the
amplitude of response and its duration for almost 2 years,
especially in those patients in whom precise assessment of
early tumor response was available. An adaptive approach,
consisting of updating the model predictions at each new
MTD observation, could be implemented to prolong the
validity period of the prediction and to enhance the percent-
age of patients for whom the minimal tumor size is suc-
cessfully predicted. These results, however, need to be
confirmed in a larger set of external patients. It would also
be interesting to evaluate the relationship between the pre-
dictive performance of the model and the timing of MTD
observations used for predictive purposes. In this study, we
focused on MTD observations obtained during the first 3
months of treatment because we wanted to obtain a refer-
ence or rational value for the predictive potential of the
model. In the area of brain tumor, numerous studies have
used partial differential equation models integrating both
time dynamics and spatial aspects of these highly diffusive
malignancies (see refs. 31,32 for examples). It would also
be important to apply the same prediction framework with
these types of models, which capture more precisely glioma
evolution.
Emergence of acquired resistance, defined as progres-
sion after initial benefits, is a critical issue in clinical oncol-
ogy and model-based approaches should be used to better
understand, characterize, and predict this phenomenon.
Mechanisms of acquired resistance can be pharmacological
resulting from decreased drug uptake into the cell, intracel-
lular drug inactivation, or repair of drug-induced damages.
This is the case of the LGG response to TMZ, for which it
has been shown that more than 90% of recurrent gliomas
show no response to a second treatment with TMZ.33 One
of the key elements in TMZ resistance is MGMT, an enzy-
matic protein with the faculty to repair the principal O6-
meG-alkylation site to TMZ,34 thus resulting in decreased
efficacy of drugs during treatment. MGMT could not be
tested as a covariate in our model since for most patients
only formalin-fixed paraffin-embedded (FFPE) tissue was
available for DNA tests, whereas MGMT methylation testing
ideally needs frozen tissue. Of note, resistance to TMZ is
also responsible for significant therapeutic failures in mela-
noma.35 Following this biological knowledge, we modeled
acquisition of resistance by decreasing drug efficacy on
LGG proliferative tissue with time following therapy onset.
Since all patients received the same TMZ doses with the
same scheduling, we believe that modeling resistance as a
function of actual drug exposure would not have led to sig-
nificantly different results. For identifiability reasons, we
could not model all transitions between the three compart-
ments, especially the possibility for quiescent cells to
directly return into proliferation, as it could occur without
treatment. However, during treatment quiescent cells do
have the capacity to repair their DNA and become prolifera-
tive. Therefore, this model is a relevant tool to characterize
tumor response to TMZ but does not aim to faithfully mimic
natural tumor growth. Our model is flexible enough to
reproduce the variability of patients’ response to standard
TMZ protocol and has the capacity to mimic both tumor
regrowth during treatment as a result of acquired resistance
to TMZ and prolonged response to treatment.
Finally, our model could constitute a rational tool to opti-
mize the duration of temozolomide therapy in low-grade gli-
oma patients. Up to now, there are no clear rules or
guidelines regarding the optimal number of cycles or treat-
ment duration in patients treated with TMZ.15 Many neuro-
oncologists prolong the duration of the treatment beyond 12
cycles if an ongoing decrease in tumor size is observed at
this time. However, there are downsides to prolonging TMZ
treatment, including side effects and costs. An even greater
concern is that TMZ therapy might drive the evolutionary
path to high-grade glioma.36 Consequently, determining the
optimal duration of TMZ therapy and maximizing the duration
of the response is a critical challenge in the management of
LGG. Using our model as a simulation tool to determine the
optimal number of TMZ cycles each patient should have
received, we found that for 47% of the 45 patients analyzed
(n5 21), the model would have recommended, by month 3
after treatment onset, administration of additional TMZ
cycles beyond what these patients actually received; i.e., in
these patients delivery of additional TMZ could have resulted
in tumor shrinkage exceeding what was ultimately achieved.
In contrast, the model predicted that 33% of the patients
(n5 15) could have benefited if their treatment had been
stopped earlier than it actually was.
Mandonnet et al. suggested that knowledge of the glioma
growth rate prior to treatment can be used to optimize
patient management and follow-up.22 Our approach pro-
poses to leverage early tumor dynamical information
together with the a tumor’s genetic characteristics to predict
tumor size response. We believe that this framework can
be used as a template for other diseases whose response
to treatment is characterized by emergence of acquired
resistance.
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